Century Therapeutics, Inc. filed a Current Report on Form 8-K on August 12, 2026, announcing its financial results for the quarter ended June 30, 2026, and furnishing an updated investor presentation.

Key Highlights

  • Quarter covered: Financial results reported for the quarter ended June 30, 2026.
  • Press release furnished: A press release dated August 12, 2026, announcing the quarterly results was furnished as Exhibit 99.1.
  • Investor presentation updated: An updated slide presentation dated August 12, 2026, was furnished as Exhibit 99.2 for use in meetings with investors.
  • Emerging growth company: Century Therapeutics indicated it qualifies as an emerging growth company under applicable securities rules.
  • Signed by CEO: The report was signed by Brent Pfeiffenberger, Pharm.D., M.B.A., President, Chief Executive Officer and Chairman of the Board of Directors.

Century Therapeutics Reports Q2 2026 Results and Updates Investor Materials

Century Therapeutics, Inc. (NASDAQ:IPSC), a Delaware-incorporated biopharmaceutical company headquartered at 25 North 38th Street, 12th Floor, Philadelphia, Pennsylvania 19104, filed a Current Report on Form 8-K with the Securities and Exchange Commission on August 12, 2026. The filing covers two items: the disclosure of financial results for the second quarter ended June 30, 2026, under Item 2.02, and a Regulation FD disclosure under Item 7.01 related to an updated investor presentation.

According to the filing, the company issued a press release on August 12, 2026, announcing its quarterly financial results, which was furnished as Exhibit 99.1. Separately, the company disclosed that it updated a slide presentation, attached as Exhibit 99.2, which representatives of the company will use "in various meetings with investors from time to time," as stated in the filing. The filing notes that the address of the company's principal executive offices changed from the 11th Floor to the 12th Floor at the same 25 North 38th Street location in Philadelphia.

The filing specifies that the information furnished under Item 2.02 and Item 7.01, including both exhibits, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," and is not incorporated by reference into other filings except as expressly set forth. The actual financial figures from the quarterly results and the content of the investor presentation were not reproduced within the body of the 8-K itself, as both are contained in the furnished exhibits.

What Was Disclosed

Century Therapeutics furnished its Q2 2026 financial results press release and an updated investor presentation on August 12, 2026, via a Current Report. Neither document's specific financial data was included in the 8-K body text itself.